574 related articles for article (PubMed ID: 24039194)
41. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
42. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
van Kooten Niekerk PB; Schmiegelow K; Schroeder H
Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
[TBL] [Abstract][Full Text] [Related]
43. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
44. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of serum and urine fetuin-A levels in children with acute lymphoblastic leukemia during and after high-dose methotrexate therapy: Relation to toxicity.
Ragab SM; Badr EA
Hematology; 2016 Mar; 21(2):78-91. PubMed ID: 26268515
[TBL] [Abstract][Full Text] [Related]
46. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.
Kapoor G; Sinha R; Abedin S
Pediatr Blood Cancer; 2012 Sep; 59(3):448-53. PubMed ID: 22271707
[TBL] [Abstract][Full Text] [Related]
47. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
48. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
49. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study.
Locasciulli A; Mura R; Fraschini D; Gornati G; Scovena E; Gervasoni A; Uderzo C; Masera G
Haematologica; 1992; 77(1):49-53. PubMed ID: 1398282
[TBL] [Abstract][Full Text] [Related]
50. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
51. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
52. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
Dhingra H; Kalra M; Mahajan A
Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
[TBL] [Abstract][Full Text] [Related]
53. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
54. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
55. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children.
Dufourg MN; Landman-Parker J; Auclerc MF; Schmitt C; Perel Y; Michel G; Levy P; Couillault G; Gandemer V; Tabone MD; Demeocq F; Vannier JP; Leblanc T; Leverger G; Baruchel A
Leukemia; 2007 Feb; 21(2):238-47. PubMed ID: 17170721
[TBL] [Abstract][Full Text] [Related]
56. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
57. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
Synold TW; Relling MV; Boyett JM; Rivera GK; Sandlund JT; Mahmoud H; Crist WM; Pui CH; Evans WE
J Clin Invest; 1994 Nov; 94(5):1996-2001. PubMed ID: 7525652
[TBL] [Abstract][Full Text] [Related]
58. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
[TBL] [Abstract][Full Text] [Related]
59. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
60. Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage.
Mangum R; Bernhardt MB; Cheng WS; Schafer ES; Berg SL; Foster JH
Pediatr Blood Cancer; 2020 Sep; 67(9):e28334. PubMed ID: 32608575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]